Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities: 2019-2025

Historic Other financing activities for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $419,000.

  • Kymera Therapeutics' Other financing activities fell 34.63% to $419,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 282.96%. This contributed to the annual value of $1.6 million for FY2024, which is 1973.68% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Other financing activities is $419,000, which was up 9.69% from $382,000 recorded in Q2 2025.
  • Kymera Therapeutics' Other financing activities' 5-year high stood at $641,000 during Q3 2024, with a 5-year trough of -$925,000 in Q4 2023.
  • For the 3-year period, Kymera Therapeutics' Other financing activities averaged around $248,182, with its median value being $334,000 (2023).
  • As far as peak fluctuations go, Kymera Therapeutics' Other financing activities soared by 222.94% in 2021, and later crashed by 403.28% in 2023.
  • Kymera Therapeutics' Other financing activities (Quarterly) stood at $156,000 in 2021, then spiked by 95.51% to $305,000 in 2022, then slumped by 403.28% to -$925,000 in 2023, then soared by 131.68% to $293,000 in 2024, then plummeted by 34.63% to $419,000 in 2025.
  • Its last three reported values are $419,000 in Q3 2025, $382,000 for Q2 2025, and $277,000 during Q1 2025.